About Biotest
Biotest is a company based in Dreieich (Germany) founded in 1946 by Carl Adolf Schleussner and Hans Schleussner was acquired by Grifols in September 2021. The company has 1,119 employees as of December 31, 2019. Biotest offers products and services including Yimmugo, Haemoctin, Cytotect, and Albiomin.
- Headquarter Dreieich, Germany
- Employees 1119 as on 31 Dec, 2019
- Founders Carl Adolf Schleussner, Hans Schleussner
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biotest Ag
-
Annual Revenue
$116.71 K (USD)210as on Dec 31, 2023
-
Net Profit
$111.84 K (USD)254as on Dec 31, 2023
-
EBITDA
Not available
-
Latest Funding Round
$266.37 M (USD), Debt – Conventional
Aug 28, 2019
-
Investors
Alcentra
& 3 more
-
Employee Count
1119
as on Dec 31, 2019
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biotest
Biotest offers a comprehensive portfolio of products and services, including Yimmugo, Haemoctin, Cytotect, and Albiomin.
Provides therapy for immune deficiencies and infections
Treats hemophilia and bleeding disorders effectively
Offers protection against viral infections in patients
Supports intensive care for volume replacement needs
People of Biotest
Unlock access to complete
Unlock access to complete
Funding Insights of Biotest
Investors in Biotest
Biotest has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Alcentra, Grifols and Berenberg.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Alcentra is engaged in alternative credit management and investment.
|
Locked | Locked | Locked | |
|
Private bank providing wealth management, corporate banking, and asset management solutions.
|
Locked | Locked | Locked | |
|
Plasma-derived therapies are developed to treat multiple diseases.
|
Locked | Locked | Locked |
Investor details for Biotest
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biotest
Investment portfolio details for Biotest
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biotest
Detailed financials for Biotest
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biotest Comparisons
Peer comparison for Biotest
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biotest
Detailed competitors of Biotest
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biotest
Complete news archive for Biotest
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biotest
Biotest was founded in 1946 and raised its 1st funding round 73 years after it was founded.
Biotest is headquartered in Dreieich, Germany. It is registered at Dreieich, Hessen, Germany.
Michael Ramroth is the current CEO of Biotest.
As of Dec 31, 2019, the latest employee count at Biotest is 1,119.
Annual revenue of Biotest is $116.71K as on Dec 31, 2023.
Biotest was founded in 1946 in Dreieich, Germany, as a manufacturer and provider of plasma proteins and biological drugs. Operations focus on the biotechnology sector, with products encompassing immunoglobulins, coagulation factors, and albumins for clinical immunology, haematology, and intensive medicine. Monoclonal antibodies are also developed in the pipeline for treating cancer and systemic lupus erythematosus.
Biotest offers Yimmugo, Haemoctin, Cytotect, and Albiomin.
Biotest has 4 investors. Key investors include Alcentra, Grifols, Berenberg, and Creat Group.